🏥 KIMS (Krishna Institute of Medical Sciences) 🚑
💊 Started in 2000 by Dr. Bhaskara Rao Bollineni and is one of the leading healthcare group in Andhra Pradesh and Telangana. It has 9 hospitals under the brand with an around a 3064-bed capacity which is 2.2 times more than the second-largest provider in AP and Telangana.
❧ MarketCap: Rs.10,135 Cr
❧ P/E:36.41 P/B: 7.36 Debt/Equity: 0.14
💊 Financial Highlights:
❧ Total income is up ⬆️ by 5% compared to the same period last year.
❧ EBITDA grew by 16 % to Rs.1218 million
❧ Consolidated PAT was up by 42% to Rs.833 million 📈
❧ EPS has increased to Rs.41.28 from Rs.26.42
What is EPS❓
It indicated the amount of money a company makes for each of its shares. Generally calculated by dividing the number of shares to a Net profit of the company.
The EBITDA margin grew to⬆️ 32.1% from 28.4% in the previous financial year.
⚙️ Operational Highlights:
❧Occupancy in the current financial year was at 58.5% compared to 57.6% in the previous year.
❧IP and OP Volumes were 17% and 22% respectively.📈
What is IP and OP Volume❓
IP (Inpatient volume): It is the amount of time a patient must remain in the hospital till the procedure is done.
OP (Outpatient Volume): It is someone who does not stay in the hospital overnight for the treatment.
❧Average Revenue per Occupied Bed (ARPOB) improved to Rs.25323 from Rs.20609.📈
❧ALOS (Average length of stay in Hospital) improved to 4.79 days from 5.33 days.🛏️
❧ ARPP (Average Revenue per Patient) increased to Rs.1.21 lakhs from 1.13 lakhs.
🏥 Recent Acquisition:
The company acquired Sunshine Hospitals, one of its hospitals at a prime location with a potential to do a business of Rs.30 Cr per month with an EBITDA of 25%.
Technicals:📈
❧ Stock currently moving in a narrow range/channel as seen on the charts.
❧ Charts are following the trendline and stock is moving near its 50 DMA levels.
❧ The stock has a positive outlook in the short to medium term considering the good fundamental and technical structure.
❧ RSI stood at 42.93 which is not positive to buy the stock technically.
❧ Ease in the covid restrictions and cased may impact the revenues of the firm.
Stock can be accumulated within a medium-term time horizon.
Medium-term outlook
Target: 1560
Stop loss: 1163
Disclaimer: The information mentioned above is only for educational purposes. Kindly contact your financial advisor before trading/investing 💰
Please share your views/querrie in the comments below. 👇
❮
❯
